A Phase III, Randomized, Open-Label Clinical Study of Napabucasin in Combination with FOLFIRI and Best Supportive Care (BSC) Versus Napabucasin plus BSC in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC)
Active, not recruitingCTIS2024-518204-50-00
1globe Health Institute LLCHistologically confirmed adenocarcinoma of the colon or rectum that is metastatic.
Start: 2022-04-25Target: 123Updated: 2025-12-10